ad image

Astellas Pharma Inc.

1 / 1
Astellas
M&A

Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.

Astellas

PR-M01-20-NI-006Jan 03, 2020
Astellas Takes Patient Centricity to the Next Level
Patient Centricity

Astellas Takes Patient Centricity to the Next Level

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-M09-19-NI-019Sep 20, 2019
Astellas
License Agreement

Astellas and Frequency Therapeutics Enter into License Agreement for FX-322, a Regenerative Treatment Candidate for Hearing Loss

Astellas

PR-M07-19-NI-055Jul 22, 2019
Astellas
BLA

Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin

Astellas

PR-M07-19-NI-050Jul 19, 2019
Actinium Pharmaceuticals, Inc.
Collaboration

Actinium Successfully Completes Second Module of Collaborative Research Program with Astellas; Third Module Initiated

Actinium Pharmaceuticals, Inc.

PR-M04-19-NI-011Apr 03, 2019
Actinium Pharma and Astellas Move to Third Phase of Their Collaboration
Collaboration

Actinium Pharma and Astellas Move to Third Phase of Their Collaboration

Nice Insight

PAO-M04-19-NI-006Apr 02, 2019
Astellas
Launch

Astellas Launches PROGRAF® Granules (tacrolimus for oral suspension) in the U.S. for Pediatric Liver, Heart, and Kidney Transplant Patients

Astellas

PR-M03-19-NI-051Mar 19, 2019
Astellas
Collaboration

Astellas and WiserCare Announce Collaboration to Improve Patient Experience

Astellas

PR-M02-19-NI-057Feb 26, 2019
Astellas
Launch

Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

Astellas

PR-M12-18-NI-057Dec 17, 2018
Astellas
Leukemia

Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Astellas

PR-M12-18-NI-025Dec 07, 2018
Astellas
Launch

Astellas Global Health Foundation Launches

Astellas

PR-M11-18-NI-087-3340Nov 26, 2018
Quethera Acquired by Astellas Pharma
Acquisition

Quethera Acquired by Astellas Pharma

Emilie Branch

Pharma's Almanac

PAO-M08-18-NI-018Aug 14, 2018
Astellas
FDA Approval

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

Astellas

PR-M07-18-NI-047Jul 16, 2018
Astellas
Appointment

Astellas names Nahrin Marino to Vice President, Head of Ethics & Compliance Americas

Astellas

PR-M06-18-NI-031Jun 11, 2018
Companies Join Forces to Develop Novel Radio-Conjugates
Radio-Conjugates

Companies Join Forces to Develop Novel Radio-Conjugates

Nigel Walker

Nice Insight

PAO-M04-18-NI-002Apr 04, 2018
Mitochondrial Expert Mitobridge Snapped Up by Astellas Pharma
Strategic Partnership

Mitochondrial Expert Mitobridge Snapped Up by Astellas Pharma

Nice Insight

PAO-M01-18-NI-002Jan 02, 2018
Astellas Completes Acquisition of Ogeda
Acquisition

Astellas Completes Acquisition of Ogeda

Guy Tiene

Nice Insight

PAO-M05-17-NI-026May 23, 2017
1 / 1